Purdue's Bid To Split OxyContin Patent Suit Gets Rejected

Law360, New York (November 26, 2013, 6:59 PM EST) -- A New Jersey federal judge on Tuesday declined to split into two phases any such trial in Depomed Inc.’s suit alleging Purdue Pharma LP's pain reliever OxyContin infringed on three of its patents for extended-release drug technology, saying bifurcation isn’t warranted.

U.S. District Judge Tonianne J. Bongiovanni denied Purdue’s motion to bifurcate the trial into two phases — one to determine liability on the alleged patent infringement and one for damages — and rejected Purdue’s argument that the case is so highly complex that a jury...
To view the full article, register now.